Further evaluation demonstrated non-scarring alopecia, subcutaneous plaques, leukopenia, hypocomplementemia, and positive antinuclear antibodies (ANA), meeting the 2019 European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) criteria for SLE. This evidence concerns the gene BTG3 and alopecia.